Genetics of Atopic Dermatitis - Eczema Herpeticum
People with atopic dermatitis (AD), or eczema, are susceptible to skin infections and inflammations. Some individuals with AD develop a condition known as eczema herpeticum (EH) following exposure to the herpes simplex virus (HSV). The purpose of this study is to identify the genetic determinants that lead people with AD to develop EH and similar conditions caused by other viruses.
Description
AD is a chronic inflammatory skin disorder characterized by recurrent viral skin infections. However, people with AD do not all develop the same infections. For example, some people with AD who receive the smallpox vaccine develop a life-threatening condition known as eczema vaccinatum (EV). This study focuses on individuals with AD who also have a history of eczema herpeticum (ADEH+), a condition similar to EV. It is unlikely that the differences in the development of skin infections are due to differences in viral exposure, and instead due to differences in each individual’s response to viruses. The purpose of this study is to determine the genetic pathways which are responsible for the development of viral skin infections in people with AD.
Participants in this study will also be enrolled in the ADVN Biomarker Registry Study. There will be only one clinical visit for this study at which blood and/or skin samples may be collected. The samples will then have high-throughput genotyping to define genetic markers in individuals susceptible to viral infections.
Status: Recruiting (N/A). Started on May 1st, 2006.
Enrollment: 900 subjects
Study Type: Observational
Study Design:
- Time Perspective: Cross-Sectional
Conditions:
Interventions:
Eligibility
Inclusion Criteria:
Enrollment in ADVN Biomarker Registry Study
Non-Hispanic and only African American or only Caucasian race
Parent or guardian willing to provide informed consent, if necessary
Exclusion Criteria:
History of any systemic illness, excluding AD
Participation of a first degree relative already enrolled in the genotyping study unless the subject in question fulfills the diagnostic criteria for ADEH+. More information on this criterion can be found in the protocol.
- Gender
Both
- Mininum Age
8 Months
- Maximum Age
80 Years
- Healthy Volunteers
Accepts Healthy Volunteers
Resources
Source: National Institute of Allergy and Infectious Diseases (NIAID)
Authority: United States: Federal Government
Locations
-
University of California at San Diego
La Jolla
California
92037
United States
-
National Jewish Health
Denver
Colorado
80206
United States
-
Northwestern University
Chicago
Illinois
United States
-
Children's Memorial Hospital
Chicago
Illinois
United States
-
Children's Hospital Boston
Boston
Massachusetts
02115
United States
-
University of Rochester Medical Center
Rochester
New York
14642
United States
-
Oregon Health & Sciences University
Portland
Oregon
97239
United States
Officials
Lisa Beck, MD (Principal Investigator, University of Rochester)
Kathleen Barnes, PhD (Principal Investigator, Johns Hopkins Allergy and Asthma Center)
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID) (Lead Sponsor)
References
Baker BS. The role of microorganisms in atopic dermatitis. Clin Exp Immunol. 2006 Apr;144(1):1-9. Review.
PMID: 16542358.
Check for Full TextKim BE, Leung DY, Streib JE, Boguniewicz M, Hamid QA, Howell MD. Macrophage inflammatory protein 3alpha deficiency in atopic dermatitis skin and role in innate immune response to vaccinia virus. J Allergy Clin Immunol. 2007 Feb;119(2):457-63. Epub 2006 Dec 4.
PMID: 17141855.
Check for Full TextPorter CD, Muhlemann MF, Cream JJ, Archard LC. Molluscum contagiosum: characterization of viral DNA and clinical features. Epidemiol Infect. 1987 Oct;99(2):563-7.
PMID: 2824227.
Check for Full TextUmene K, Yoshida M, Sakaoka H. Comparison of the association with eczema herpeticum in the two predominant genotypes of herpes simplex virus type 1. J Med Virol. 1996 Aug;49(4):329-32.
PMID: 8877767.
Check for Full Text
Links
- Date Verified
- May 1st, 2011
- First Received
- May 5th, 2011
- Last Changed
- May 5th, 2011
Information obtained from ClinicalTrials.gov on June 09, 2011. Link to the current ClinicalTrials.gov record.
All data in the Healia Clinical Trials Information Database and content displayed by the Healia Clinical Trials Search Engine are licensed from the National Institutes of Health (National Library of Medicine), which collects and maintains the data.
The Healia Clinical Trials Search Engine searches the data set at clinicaltrials.gov, providing up-to-date information about current clinical trials. In the Healia Clinical Trials Database you can find information on new experimental drugs, medical devices, and other types of treatments for all types of diseases. Each clinical trial description includes information about the phase of the trial (phase I, phase II, or phase III), the trial’s methods, such as whether it is a randomized, placebo controlled, double blind study, and the status of the trial including whether or not the trial is currently enrolling new participants.